The FDA’s authorisation of Medtronic’s BrainSense follows the system’s receipt of a CE mark in Europe last month.

For the one million people diagnosed with Parkinson's disease in the United States1, Medtronic plc (NYSE:MDT), a global leader in healthcare technology, proudly announces U.S. Food and Drug ...

Medtronic强调，其BrainSense™技术通过实时监测大脑信号，能够对患者病情提供独特见解。公司致力于创造适应现实场景的解决方案，这一点在aDBS的开发中得到了充分体现，预计将为帕金森病治疗树立新标准。

The BrainSense adaptive deep brain stimulation system personalizes therapy by dynamically adjusting stimulation based on real ...

The FDA approved Medtronic's BrainSense Adaptive DBS and Electrode Identifier for Parkinson's, enhancing therapy ...

(NYSE: MDT) announced today that the FDA approved its BrainSense adaptive deep brain stimulation (aDBS) platform.

The closed-loop system dynamically self-adjusts DBS therapy to individual brain activity in real time, providing personalized ...

The FDA has approved adaptive deep brain stimulation (aDBS), a breakthrough therapy that adjusts in real time to Parkinson’s disease symptoms.

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of ...

Shortly after obtaining a greenlight in Europe and after more than 10 years in development, Medtronic has now received the ...

Medtronic (MDT) announced FDA approval of BrainSense Adaptive deep brain stimulation – aDBS – and BrainSense Electrode Identifier. There is no cure for debilitating neurological conditions like ...

Earlier this year, Medtronic received approval from European regulators for its adaptive deep brain stimulation (aDBS) technology, which includes an implant that can dynamically adjust signals to ...